COVID-19. SARS-associated coronavirus as the cause of diseases classified elsewhere
Conditions
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 2019-nCov (SARA-Cov-2) nucleic acid positive will be detected by PCR in affected patients older than 17 years old and younger than 76 years old. No medications or disorders that would affect vitamin D metabolism Women must be not pregnant at baseline and during study Ability and willingness to give informed consent and comply with protocol requirements
Exclusion criteria
Exclusion criteria: Ongoing treatment with pharmacologic doses of vitamin D, vitamin D metabolites or analogues Pregnant or lactating women; Severe underlying diseases, such as advanced malignant tumor, end-stage lung disease, etc. History of elevated serum calcium >9.8 mg/dl) Chronic hepatic or renal failure or patients with reduced kidney function, cancers, and malabsorption syndrome, a granulomatous disorders such as Sarcoidosis or Tuberculosis Supplementation with over the counter formulations of vitamin D2 or vitamin D3 Use of tanning bed or artificial UV exposure within the last two weeks. Consuming medication affecting bone metabolism (anti-convulsants, anti-tuberculosis medication, cimetidine, theophylline, and cholestyramine), as well as those who are following special diets such as vegetarian diet or consuming fortified products regularly. Subjects with a history of an adverse reaction to orally administered vitamin D, vitamin D metabolites or analogues. Inability to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Infection duration. Timepoint: during study. Method of measurement: WHO criteria. | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of disease (mild, moderate, sever). Timepoint: during study. Method of measurement: Dyspnea, Palsoximethry result, CBC diff, Blood gas parameters, and acid-base, CT scan result.;Serum levels of Vitamin D. Timepoint: before intervention, end of 4th and end of 8th intervention. Method of measurement: HPLC method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZhila Maghbooli
Tehran University of Medical Sciences
Outcome results
None listed